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Efficiency of Canonical Discriminant Function versus Mahalanobis Distance in 
Differentiating Groups: Screening Ovarian Cancer in a Multivariate System 
Analysis Using Enzyme Markers 
 
Chinmoy K. Bose 
Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, India 
 
 
Due to its low prevalence, high mortality and uniquely hidden intrapelvic position, ovarian cancer 
remains a subject of intense interest to researchers. Statistical calculation and new technology both have 
major roles to play in the effort to screen this cancer at an early stage. Advanced statistics, such as 
multivariate analysis, remain at the root of screening endeavors. Multivariate analysis has the power to 
combine many tests and to produce better results in terms high specificity and positive predictive value. 
Multivariate analysis techniques include Mahalanobis distance (D2), canonical stepwise discriminant 
function (Z) and Posterior Probability. These may have varied efficacy, but to date comparisons have not 
been conducted to determine which is best in the context of ovarian cancer screening. 
 
Key words: Multivariate analysis, Mahalanobis distance (D2), canonical stepwise discriminant function 
(Z), posterior probability, ovarian cancer screening, tumor marker. 
 
 
Introduction 
 
With an overall survival rate of 30%, ovarian 
cancer remains the fifth leading cause of cancer 
death. This disease, which is neither common 
nor rare (Bast, 2004), has remained enigmatic 
amongst gynecological cancers with agonizing 
prospects. Ovarian cancer is the second most 
common gynecologic malignancy, and little is 
known about the progression of its early changes 
(dysplasia). 
Ovarian cancer has the highest mortality 
rate among gynecologic malignancies (70%) and 
its mortality rate has not lowered in the last 50 
years. Only 25% of cases are diagnosed in an 
early stage and late case diagnosis survival is 
very poor. Though tests such as tumor markers 
and ultrasounds are available, no cost-effective  
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screening method with adequate sensitivity and 
specificity is available to detect early ovarian 
cancer. 
Combining markers and tests results in 
higher sensitivity and specificity, thus, many 
scientists have used multivariate analysis in their 
experiments. In an ovarian cancer screening 
system, multivariate stepwise discriminant 
function analysis is described using different 
tumor markers, for example, CA125, TPA, IAP, 
CEA, and ferritin (Yabushita, et al., 1985; 
LaHousen, et al., 1987). Kobayashi and Terao 
(1992) combined CA 125, TPA, Ferritin, CEA, 
AFP and Sialyl Lewis Xi using Mahalanobis 
distance and were able to decrease both false 
positive and false negative cases. Bose and 
Mukherjea (1994) statistically combined several 
enzymatic tumor markers to increase specificity, 
positive predictive value (PPV) and to decrease 
false positive tests. 
Other groups described combining 
multiple markers, but they either combined them 
in a statistically unacceptable way (Inoue, Fujita, 
Nakazawa, Ogawa & Tanizawa, 1992), in a 
simple Euclidian relationship, such as the risk of 
malignancy Index (RMI, Oram, et al.,1990; 
Jacobs, et al., 1990) or otherwise (Jacobs, et al., 
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1990). Jacobs, Oram & Bast (1992) used a 
multivariate system while also using 
apolipoprotein A1 (down-regulated in cancer); a 
truncated form of transthyretin (down-regulated) 
and a cleavage fragment of inter- -trypsin 
inhibitor heavy chain H4 (up-regulated). 
Zhang, Bast, et al. (2004) described the 
risk of ovarian cancer (ROC) algorithm. They 
combined the parameters Serial CA125 assay 
value, changes in CA125 levels over time and 
woman’s age, and assay variability by a 
multivariate based software program, which they 
called the ROC algorithm. However, they did 
not describe the actual procedure they followed. 
They speculated sensitivity 86%, specificity 
99.7%, and PPV up to 19% which is 
encouraging (Menon, et al., 2005). They are now 
conducting a massive trial on population 
screening in the UK, which will take another 
two years to complete. 
Timmerman, et al. (2005) combined 12 
useful independent prognostic variables in a 
logistic regression model and found a 
probability cut off value of 0.10 that gave a 
sensitivity of 93% and a specificity of 76%. 
Curling, et al. (1998) conducted a multivariate 
analysis of DNA ploidy, steroid hormone 
receptors and CA 125 as prognostic factors in 
ovarian carcinoma, and Kozak, et al. (2005) 
used multivariate analysis to greatly improve the 
detection of early stage ovarian tumors 
compared to cancer antigen CA125 alone with 
the help of differential expression of 
transthyretin (TTR), beta-hemoglobin (Hb), 
apolipoprotein AI (ApoAI) and transferrin (TF). 
Multivariate procedures include 
Mahalanobis distance (D2), canonical stepwise 
discriminant function (Z) and Posterior 
Probability, but no research has been conducted 
to determine whether they are equally effective 
in detection systems for screening ovarian 
cancer using multiple parameters. 
 
Methodology 
 
Serum levels of four enzyme makers (placental 
alkaline phosphatase, lactate dehydrogenase, 5' 
nucleotidase and Amylase) were measured using 
a commercially available kit, in 50 ovarian 
cancer patients and 31 patients with benign 
gynecological disease before initiation of any 
treatment. These were compared with the levels 
in a control group of 30 healthy women using 
different multivariate parameters Mahalanobis 
distance (D2), canonical stepwise discriminant 
function (Z) and Posterior Probability. The goal 
was to determine if any difference exists in the 
power of detection of disease state by these 
methods and if one is more or most efficient in 
detecting disease state. 
Data for all enzyme levels in different 
groups were fed into a DIGITAL-VAX 8650 
computer using a VMS operating system. 
BMDP 1990 version software program packages 
3D and 7M were used to analyze the data. In 
BMDP 3D, mean, standard deviation, standard 
error of mean and pooled T test were used to 
show significant group differences separately for 
each enzyme. Sensitivity and specificity for each 
enzyme were determined at different cut off 
scores and a Receiver Operator Characteristic 
Curve (ROC) was prepared to compare the 
efficacy of individual enzyme. 
In the same program, Hotelling’s T2 test, 
F, p for four enzymes taken together at a time 
(multivariate analysis) were obtained and were 
analyzed to observe significant differences 
between different groups. The F value was 
observed and, if it significantly exceeded unity, 
the two groups were assumed to be statistically 
significantly different. 
If a random sample of size n yields the 
sample value x1, x2, x3,…, xn 
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then these are estimates of corresponding 
population parameters – the population mean μ 
and the population variance σ2. 
In a similar way, multivariate population 
can be summarized by mean vectors and 
covariance matrices. These are defined as 
follows. If there are p variables x1, x2, x3, …, xp 
and the values of these for the ith individual in a 
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sample are xi1, xi2, xi3, …, xip respectively, then 
the sample mean of variable j is 
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and the sample variance is 
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In addition the sample covariance between 
variable j and k is defined as 
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The pooled estimate of variance from the two 
sample n1 and n2 is, 
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the matrix of covariances (C 1 and C 2) 
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the pooled estimate of covariance matrix is 
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and Hotelling’s T2 statistics is defined as 
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A significantly large value for these statistics is 
evidence that the mean vectors are different for 
the two sample populations. The significance or 
the lack of significance of T2 is most simply 
determined by using the null hypothesis case of 
equal population means for the transformed 
statistics. 
The analysis of variance (also known as 
Snedecor’s F or the Fisher-Snedecor F) test is 
based on the continuous F-distribution, which is 
a random variate arising as the ratio of two Chi-
squared variates: 
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where U1 and U2 have Chi-square distributions 
with d1 and d2 degrees of freedom respectively, 
and U1 and U2 are independent. Thus,  
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Because T2 is a quadratic form it is scalar, and 
can be written in as 
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which is simpler to compute. Here xji is the mean 
of the variable xi in the jth sample and cik is the 
element in the ith row and the kth column of the 
inverse matrix C-1. 
BMDP 7M was used for multivariate 
stepwise canonical discriminant function 
analysis. To separate the different groups of 
patients, following simple linear combination 
was used 
 
1 1 2 2 3 3 4 4.Z K a X a X a X a X= + + + +  
 
Z is the canonical discriminant function of 
variable enzymes namely X1 = PLAP, X2 = 
LDH, X3 = 5’N, X4 = Amylase, whereas a1, a2, 
a3, and a4 are the coefficients of the above 
variable respectively and K is the constant. 
Coefficient and constant were determined by 
using BMDP. 
Mahalanobis distance of individuals to 
group centers can be calculated by the following 
formula 
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while the posterior probability is 
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where p is probability, A is the abnormality, and 
PT is the positive test result. Thus, the 
expression on the left, P (A: PT) is equivalent to 
the probability P of abnormality A given the 
positive test result PT. This is described as 
posterior probability and is in Bayes’ theorem, 
which relates the conditional and marginal 
probabilities of stochastic events A and B: 
 
Pr(A B) Pr(BA)Pr(A (A B) Pr(A)
Pr(B)
L⏐ ⏐⏐Β) = ∝ |
 
where L(A|B) is the likelihood of A given fixed 
B. Each term in Bayes’ theorem has a 
conventional name. Pr(A) is the prior probability 
or marginal probability of A. It is prior in the 
sense that it does not take into account any 
information about B. Pr(A|B) is the conditional 
probability of A given B; it is also called the 
posterior probability because it is derived from 
or depends upon the specified value of B. 
Pr(B|A) is the conditional probability of B given 
A. Pr(B) is the prior or marginal probability of 
B, and acts as a normalizing constant. The 
posterior probability is proportional to the prior 
probability times the likelihood. 
Both D2 and PP were determined 
through the same package. The ROC curve of 
individual marker enzymes showed LDH to be 
most sensitive and specific. Thus, LDH was 
compared with these three multivariate systems 
in Receiver Operator Characteristic (ROC) 
chart. 
In healthy women discriminant function 
(Z), Mahalanobis distance (D2) and posterior 
probability (PP) were determined for each case. 
Their mean and standard deviation were 
compared with the values of corresponding 
multivariate parameters for each individual in 
both the benign gynecological disease (BGD) 
and ovarian cancer group. When plotted with 
chosen cut-off scores with their corresponding 
(1−specificity) in x axis and sensitivity in y axis 
the ROC curve will show comparative efficacy 
of Z over D2, PP and LDH in terms of largest 
area under the graph. 
 
Results 
 
Table 1 shows the serum concentration of four 
enzymes markers, placental alkaline 
phosphatase, lactate dehydrogenase, 5' 
nucleotidase and Amylase, with their mean ± 
standard error of mean. Results of enzyme 
estimations of three groups, Healthy control, 
Benign gynecological disease (BGD) and 
Ovarian cancer are shown in three columns. 
Significant differences are also shown as p 
values. Although activities of all enzymes have 
been found to be significantly higher in ovarian 
cancer cases than in healthy women, positivity 
rates were not very high. The positivity rate 
measured for each enzyme in ovarian cancer, 
showed LDH to be the most sensitive (positivity 
48%), whereas amylase showed least sensitivity 
at a positivity rate of 30%. However, these are 
much lower compared to the positivity rate 
(75%) of cancer antigen CA 125, the most 
sensitive tumor marker in ovarian cancer 
(Heinonen, Kallinoiemi & Koivula, 1987). 
Test results in the ovarian cancer group 
were significantly different from the healthy 
control group, but showed no statistically 
significant difference with the benign 
gynecological disease (BGD) group. 
Table 2 shows sensitivity and specificity 
of serum enzymes markers at different cut-off 
concentrations. Table 3 summarizes the cut-off 
scores of the markers that had the highest 
sensitivity and specificity. They were compared 
with CA125 at a suitable cut off level of 35 
IU/L. LDH had the highest sensitivity and 
specificity at a cut off score of 157.88 IU/L but 
it still fell behind CA125. 
With different sensitivity and specificity 
at cut-off values of those enzyme markers, a 
Receiver Operator Characteristic Curve (ROC) 
was prepared to compare the power and efficacy 
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of individual enzymes to differentiate between 
groups in a univariate system (Figure 1). 
Four serum enzymes are used at a time 
in multivariate analysis by the BMDP package 
(program 3D), where a significant group 
difference was observed between healthy versus 
ovarian cancer and BGD versus ovarian cancer 
patients; in healthy versus BGD there was no 
statistically significant difference (Table 4.). Z, 
D2 and PP were obtained through program 7M 
for healthy versus ovarian cancer patients. 
Sensitivity and specificity of LDH, Z, D2 and 
PP at different cut-off scores or action lines with 
their confidence interval (derived from the 
binomial distribution chart) for healthy women 
and ovarian cancer cases are shown in Table 5. 
Table 6 compares sensitivity and specificity of 
different multivariate parameters such as, LDH, 
Z, D2 and PP.  
The performance of the canonical 
discriminant function (Z) at various upper limits 
is illustrated in the ROC chart (Figure 2) and is 
observed to combine higher levels of sensitivity 
and specificity than those achieved by 
Mahalanobis distance (D2), PP and LDH. Table 
7 shows the positive and negative predictive 
values for malignancy of ovary for different 
levels of Z (cutoff scores 1.377, 2.907. 3.437 
and 5.967). A cut-off score of 3.437 produced 
the best results. No statistically significant group 
difference was predicted between healthy and 
BGD, which was corroborated by the 
determination of Z value. 
 
Conclusion 
 
The population screening of ovarian cancer has 
remained elusive due to low disease prevalence 
and low positive predictive value of the tests. 
Some groups are trying to combine different test 
results in different software packages using 
algorithms based on multivariate systems of data 
processing, but many alternatives in this 
multivariate system exist which are not based on 
some type of mathematical calculation. As a 
result, finding more efficacious methods in 
terms of higher specificity and higher positive 
predictive value is a priority. This system is 
applicable in many areas in biology and 
medicine. This article presented an example of 
the use of multivariate analysis in ovarian cancer 
screening to illustrate the comparative efficacy 
of stepwise discriminant function (Z) 
Mahalanobis distance (D’) and posterior 
probability (PP).  
It is expected that this example will be 
replicated in other experimental circumstances, 
but will need further verification and 
establishment of mathematical proof as to why it 
occurs. In the experiment presented, it was 
observed that the Multivariate stepwise 
discriminant function (Z) analysis of enzyme 
variables establishes an easy quantitative 
assessment method of the risk of malignancy in 
the ovary. A Z value with a cut-off score of 
3.437 has a higher predictive value and relative 
risk than LDH, Mahalanobis distance (D2) or 
posterior probability (PP). This system of 
combining four enzymes for improvement of 
ovary screening must be established in clinical 
practice through further research. 
 
References 
 
Bast, R. C. Jr. (2004). Early detection of 
ovarian cancer: New technologies in pursuit of a 
disease that is neither common nor rare. Trans 
American Clinical Climatological Association, 
115, 233-248.  
Bose, C. K., & Mukherjea, M. (1994). 
Enzymatic tumor markers in ovarian cancer: a 
multiparametric study. Cancer Letters, 77(1), 
39-43 
Curling, M., Stenning, S., Hudson, C. 
N., & Watson, J. V. (1998). Multivariate 
analyses of DNA index, p62c-myc, and 
clinicopathological status of patients with 
ovarian cancer. Journal of Clinical Pathology, 
51(6), 455-461. 
Heinonen, P. K., Kallinoiemi. O. P., & 
Koivula. T. (1987). Comparison of CA 125 and 
placental alkaline phosphatase as ovarian tumour 
markers. Tumori, 73(3), 301-302. 
Inoue, M., Fujita, M., Nakazawa, A., 
Ogawa, H, Tanizawa, O. (1992). Sialyl-Tn, 
sialyl-Lewis Xi, CA 19-9, CA 125, 
carcinoembryonic antigen, and tissue 
polypeptide antigen in differentiating ovarian 
cancer from benign tumors. Obstetrics and 
Gynecology, 79, 434-440. 
 
 
BOSE 
 
311 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Serum Concentration of Enzymes Markers Mean ± SEM 
Enzymes Healthy Control 
Benign 
Gynecological 
Disease (BGD) 
Ovarian Cancer 
Placental alkaline 
phosphatase (IU/L) 0.81± 0.09 
1.76 ± 0.47 
(P< .0615) 
4.47 ± 0.89 
(P< .0011) 
Lactate 
dehydrogenase 
(IU/L) 
157.88 ± 8.61 155.65 ± 7.88 (P< .8497) 
255.44 ± 16.19 
(P< .0001) 
5' nucleotidase 
(IU/L) 5.94 ± 0.75 
5.22 ± 0.42 
(P< .4098) 
9.13 ± 0.93 
(P< .0191) 
Amylase (IU/L) 79.1 ± 3.83 77.8 ± 3.38 (P< .6828) 
121.54 ± 8.23 
(P< .0001) 
 
Table 2: Sensitivity and Specificity of Serum Enzymes Markers at 
Different Cut-off Concentrations 
Test and Action Line 
(cutoff score in IU/L) Sensitivity Specificity 
LDH 
110.73 
157.88 
205.03 
252.18 
94 
88 
50 
34 
20 
63 
90 
93.3 
Amylase 
75.25 
79.1 
83.93 
86.76 
76 
74 
68 
64 
43.3 
53.3 
60 
60 
PLAP 
0.72 
0.81 
0.90 
64 
60 
58 
50 
60 
66.6 
5’Nucleotidase 
5.19 
5.94 
6.69 
7.44 
56 
54 
42 
39 
56.6 
63.6 
66.6 
66.6 
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Table 3: Cut-off Score Offering Highest Sensitivity and Specificity 
Cutoff Scores (IU/L) Enzyme Markers Sensitivity Specificity 
0.90 Placental alkaline phosphatase (IU/L) 58 66.6 
157.88 Lact dehydrogenase (IU/L) 88 63 
83.93 Amylase (IU/L) 68 60 
5.95 5' nucleotidase(IU/L) 54.8 64.3 
35 CA125 72 75 
Figure 1: Receiver Operator Characteristic Curve (ROC) to Compare the Power of 
Individual Enzymes 
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Table 4: Mahalanobis Distance (D2) Hotelling's T2 F & P Value to Predict Multivariate Based 
Statistical Significance of Different Between Groups 
Group Difference Mahalanobis Distance (D2) 
Hotelling's 
T2 F P 
Healthy women vs. ovarian cancer 2.7061 50.7390 12.1969 0.0001 
Healthy women vs. Benign gyn. disease 0.2992 4.5611 1.0823 0.3741 
Ovarian cancer vs. Benign gyn. disease 2.4808 54.3602 13.0740 0.0001 
Ovarian cancer vs. non-responder 0.0530 1.0721 0.2582 0.9028 
Ovarian cancer vs. responder 1.3802 12.444 2.9528 0.0277 
 
Table 5: Sensitivity and Specificity of Multivariate Based Statistical Parameters 
Compared With LDH at Different Cut-off Concentrations 
Test and action line 
(cutoff score in IU/L) 
Sensitivity Specificity 
% (95% CI) % (95% CI) 
LDH 
110.73 
157.88 
205.03 
252.18 
94 
88 
50 
34 
(82-99) 
(82-99) 
(82-99) 
(82-99) 
20 
63 
90 
93.3 
(82-99) 
(82-99) 
(82-99) 
(82-99) 
Z 
1.337 
2.907 
3.437 
5.967 
98 
96 
96 
76 
(88-100) 
(86-99) 
(86-99) 
(61-87) 
13 
70 
83 
93.3 
(82-99) 
(82-99) 
(82-99) 
(82-99) 
D2 
0.09 
0.93 
1.77 
2.61 
100 
86 
82 
74 
(92-100) 
(72-94) 
(68-91) 
(59-86) 
0 
73 
86.6 
93 
(0-12) 
(54-87) 
(66-96) 
(77-99) 
PP 
0.525 
0.726 
0.887 
1.048 
80 
92 
96 
100 
(67-90) 
(80-92) 
(86-99) 
(92-100) 
90 
76.6 
20 
0 
(72-97) 
(56-89) 
(10-58) 
(0-12) 
Table 6: Sensitivity and Specificity of Different Multivariate Parameters 
Such as, LDH, Z, D2 and PP 
Statistics Sensitivity Specificity 
Mahalanobis Distance 
D2 = 1.77 82 86.3 
Posterior Probability 
Pp = 0.726 92 76.6 
Discriminant Function 
Z = 3.437 96 83 
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Table 7: Positive and Negative Predictive Value for 
Different Levels of Z 
Z Score 
Predictive Value (%) 
Positive Negative 
1.337 91.3 3.7 
2.907 91.3 9.6 
3.437 84 92 
5.967 70 95 
 
Figure 2: Receiver Operator Characteristic Curve (ROC) to Compare the Power of Multivariate Based 
Statistical Parameters Compared with LDH 
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